Pulmonary arterial hypertension and Paranasal sinus hypersecretion

Summary:

Paranasal sinus hypersecretion is found among people with Pulmonary arterial hypertension, especially for people who are female, 60+ old.

The study analyzes which people have Paranasal sinus hypersecretion with Pulmonary arterial hypertension. It is created by eHealthMe based on reports of 183 people who have Pulmonary arterial hypertension from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

183 people who have Pulmonary Arterial Hypertension and Paranasal Sinus Hypersecretion are studied.

What is Pulmonary arterial hypertension?

Pulmonary arterial hypertension (high blood pressure in the arteries of lungs) is found to be associated with 1,220 drugs and 756 conditions by eHealthMe.

What is Paranasal sinus hypersecretion?

Paranasal sinus hypersecretion is found to be associated with 729 drugs and 393 conditions by eHealthMe.

Number of Paranasal sinus hypersecretion in Pulmonary arterial hypertension reports submitted per year:

Would you have Paranasal sinus hypersecretion when you have Pulmonary arterial hypertension?

Gender of people who have Pulmonary arterial hypertension and experienced Paranasal sinus hypersecretion *:

Click here to view

Age of people who have Pulmonary arterial hypertension and experienced Paranasal sinus hypersecretion *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Paranasal sinus hypersecretion?

Check whether Paranasal sinus hypersecretion is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hung YM, Cheng CC, Wann SR, Lin SL, "Ankylosing spondylitis associated with pulmonary arterial hypertension", Internal Medicine, 2016 Jan .

Related studies

Treatments, associated drugs and conditions:

Pulmonary arterial hypertension (200,569 reports)
Paranasal sinus hypersecretion (4,043 reports)

COVID vaccines that are related to Paranasal sinus hypersecretion:

Common drugs associated with Paranasal sinus hypersecretion:

Aspirin: 232 reports
Enbrel: 868 reports
Humira: 569 reports
Hydrochlorothiazide: 115 reports
Lisinopril: 147 reports
Metformin: 122 reports
Methotrexate: 292 reports
Omeprazole: 129 reports
Prednisone: 275 reports
Repatha: 158 reports
Synthroid: 127 reports
Vitamin d: 128 reports

All the drugs that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (729 drugs)

Common conditions associated with Paranasal sinus hypersecretion:

Asthma: 108 reports
Blood cholesterol increased: 221 reports
Crohn's disease: 146 reports
High blood cholesterol: 221 reports
High blood pressure: 139 reports
Ldl/hdl ratio increased: 221 reports
Lipoprotein test: 221 reports
Multiple sclerosis: 149 reports
Osteoporosis: 135 reports
Primary pulmonary hypertension: 183 reports
Psoriasis: 271 reports
Psoriatic arthropathy: 215 reports
Pulmonary arterial hypertension: 183 reports
Ra: 887 reports
Rheumatoid arthritis: 887 reports

All the conditions that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (393 conditions)

How the study uses the data?

The study is based on Paranasal sinus hypersecretion and Pulmonary arterial hypertension, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.